ANI Pharmaceuticals Company Profile (NASDAQ:ANIP)

Analyst Ratings

Consensus Ratings for ANI Pharmaceuticals (NASDAQ:ANIP) (?)
Ratings Breakdown: 1 Hold Rating(s), 4 Buy Rating(s), 1 Strong Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $59.50 (1.15% downside)

Analysts' Ratings History for ANI Pharmaceuticals (NASDAQ:ANIP)
Show:
DateFirmActionRatingPrice TargetActions
7/19/2016Citigroup Inc.UpgradeOutperform$65.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/22/2016Raymond James Financial Inc.Initiated CoverageStrong-Buy$68.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/17/2016GuggenheimReiterated RatingBuy$55.00 -> $65.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/24/2016Standpoint ResearchDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/3/2016Oppenheimer Holdings Inc.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/4/2015Roth CapitalReiterated RatingBuy$60.00 -> $56.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/28/2014 forward)

Earnings

Earnings History for ANI Pharmaceuticals (NASDAQ:ANIP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/2/2016        
5/5/2016Q116$0.64$0.76$21.03 million$20.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/23/2016Q415$0.60$0.52$18.13 million$18.04 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2015Q315$0.63$0.80$21.37 million$20.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2015Q215$0.54$0.31$20.30 million$19.52 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2015Q115$0.56$0.57$19.86 million$18.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/19/2015Q414$0.58$0.67$17.98 million$21.04 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2014Q314$0.46$0.66$14.60 million$17.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2014Q214$0.01($0.21)$7.95 million$6.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2014Q115$0.32$0.33$11.40 million$10.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2014Q414$0.35$5.32 million$10.53 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2013$0.16ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ANI Pharmaceuticals (NASDAQ:ANIP)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161$0.24$0.24$0.24
Q2 20161$0.78$0.78$0.78
Q3 20161$0.94$0.94$0.94
Q4 20161$1.06$1.06$1.06
(Data provided by Zacks Investment Research)

Dividends

Dividend History for ANI Pharmaceuticals (NASDAQ:ANIP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for ANI Pharmaceuticals (NASDAQ:ANIP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
12/18/2015James G MarkenVPSell3,500$43.26$151,410.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2015Arthur PrzybylCEOBuy2,500$40.95$102,375.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/19/2015James G MarkenVPSell15,000$66.50$997,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2014Ross J ManganoDirectorBuy3,000$27.49$82,470.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/9/2014Arthur PrzybylCEOBuy1,000$26.50$26,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2014James G MarkenVPSell5,000$34.28$171,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/8/2014Tracy MarshbanksDirectorSell1,381$30.02$41,457.62View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/7/2014Ross ManganoDirectorBuy2,000$30.38$60,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/21/2014Tracy MarshbanksDirectorSell21,767$31.42$683,919.14View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/20/2014Meridian Venture Partners Ii Lmajor shareholderSell20,922$32.12$672,014.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/19/2014Tracy MarshbanksDirectorSell25,358$33.68$854,057.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/18/2014Meridian Venture Partners Ii Lmajor shareholderSell60,540$34.07$2,062,597.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/13/2014Meridian Venture Partners Ii Lmajor shareholderSell87,723$32.48$2,849,243.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/7/2013Ross J ManganoDirectorBuy9,000$11.27$101,430.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2013Ross J ManganoDirectorBuy10,000$7.47$74,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for ANI Pharmaceuticals (NASDAQ:ANIP)
DateHeadline
07/28/16 11:13 AMBioMarin Pharmaceutical (BMRN) Jumps: Stock Rises 6.6%
07/28/16 11:13 AMANI PHARMACEUTICALS INC : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)
07/28/16 07:48 AMANI Pharmaceuticals Schedules Conference Call to Discuss Second Quarter and Year-to-Date 2016 Financial Results - [at noodls] - BAUDETTE, Minnesota (July 28, 2016) - ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its second quarter and year-to-date 2016 financial results on Thursday, ...
07/28/16 07:37 AMANI PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E -
07/27/16 10:44 AMCuris (CRIS) in Focus: Stock Adds 5.7% in Session
07/25/16 07:17 AMIs $68 Price Target Attainable For ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)? - Investor Newswire
07/22/16 10:40 AMLasalle Street Capital Management adds ANI Pharmaceuticals Inc (ANIP) to its portfolio - TheFounders Daily
07/22/16 07:15 AMAVEO Pharmaceuticals (AVEO) Catches Eye: Stock Up 10.4% -
07/21/16 07:25 AMLigand Pharmaceuticals (LGND) Jumps: Stock Rises 5.5% -
07/20/16 09:57 PMANI Pharmaceuticals Inc. (ANIP) is Trading Higher on Unusual Volume for July 19 - Equities.com
07/20/16 03:38 PMTrading Action Review: Watching Unusual Volume on ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Engelwood Daily
07/20/16 09:31 AMMoody's: FDA Approval of Generic Nilandron is Credit Negative for Concordia; no change to rating or outlook -
07/19/16 07:55 PMANI Pharma Announces FDA Approval And Immediate Launch Of Nilutamide Tablets
07/19/16 08:41 AMInvestor Watch: Volatility Recap on Shares of: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Engelwood Daily
07/19/16 08:41 AMANI Pharma (ANIP) Receives FDA Approval for Nilutamide Tabs ANDA - StreetInsider.com
07/18/16 12:33 PMANI Pharmaceuticals Gets FDA Approval And Immediate Launch Of Nilutamide Tablets -
07/18/16 07:31 AM8:31 am ANI Pharma announces that it has received approval from the FDA for the abbreviated new drug application for nilutamide tablets -
07/18/16 07:30 AMANI Pharmaceuticals Announces FDA Approval and Immediate Launch of Nilutamide Tablets, the First Generic Competitor to Nilandron® - [PR Newswire] - BAUDETTE, Minn., July 18, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (ANIP) today announced that it has received approval from the U.S. Food and Drug Administration ("FDA") of the Abbreviated New Drug Application ("ANDA") for nilutamide tablets. Trailing twelve-month sales of Nilandron® were $23 million according to IMS Health. ANI will immediately launch the product. Arthur S. Przybyl, ANI's President and CEO stated, "The nilutamide approval exemplifies ANI's strategic focus to introduce high barrier niche generic products. We are excited to have secured approval for a first-to-market generic that represents ANI's second entry into the anti-cancer market and leverages our specialized high-potent manufacturing capability at our plant in Baudette, MN.
07/18/16 07:20 AMShare Performance Summary for: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Press Telegraph
07/18/16 07:20 AMWere Analysts Bullish ANI Pharmaceuticals Inc (NASDAQ:ANIP) This Week? - Consumer Eagle
07/18/16 07:20 AMStock in Positive Territory for the Quarter: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Engelwood Daily
07/18/16 07:20 AMStrong Sell Calls For ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) At 0 - Investor Newswire
07/17/16 02:26 PMReview on Stock Valuation for: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - TGP
07/17/16 07:16 AMNext Weeks Broker Price Targets For ANI Pharmaceuticals, Inc. (ANIP) - Fiscal Standard
07/16/16 10:53 AMShares Experiencing a Downtrend: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - TGP
07/13/16 02:30 PMNew Broker Ratings For ANI Pharmaceuticals, Inc. (ANIP) - FTSE News
07/13/16 02:30 PMANI Pharmaceuticals Inc Realized Volatility Hits Extreme Level - CML News
07/12/16 06:47 AMShares Positive on the Year: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Telanagana Press
07/11/16 02:29 PMStock Performance Rundown on: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Press Telegraph
07/11/16 07:18 AMShare Valuation Recap for: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Telanagana Press
07/11/16 07:18 AMIs $68 Within Reach For ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)? - Investor Newswire
07/06/16 08:16 PMShort Information Review for: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Engelwood Daily
07/05/16 10:28 AMMerck to Acquire Brazilian Animal Health Company for $400M -
07/04/16 02:28 PMShares With YTD Gains: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Telanagana Press
07/04/16 02:28 PMAni Pharmaceuticals Incorporated (NASDAQ:ANIP) Shorted Shares Increased By 7.53% - Press Telegraph
07/04/16 02:28 PMShare Performance Recap for: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Press Telegraph
07/04/16 08:06 AMXBiotech Xilonix Positive in Phase III Colorectal Cancer Study -
07/04/16 08:06 AMXBiotech Xilonix Positive in Phase III Colorectal Cancer Study -
07/04/16 07:18 AMANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Expected to Reach Highs Of $68 - Investor Newswire
07/03/16 07:16 AMStock Valuation in Review: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Telanagana Press
07/01/16 02:30 PMHealthcare Value Capital LLC Increased Ani Pharmaceuticals INC (NASDAQ:ANIP) by $12.21 Million as Shares ... - Press Telegraph
06/30/16 02:38 PMRaymond James Initiates Coverage on ANI Pharmaceuticals Inc to Strong Buy - Trade Calls
06/30/16 02:38 PMANI Pharmaceuticals Inc. (ANIP) is Trading Higher on Unusual Volume for June 28 - Equities.com
06/30/16 10:21 AMHorizon (HZNP) Stock Up on Ravicti Label Expansion Filing
06/29/16 07:38 PMShort Data Recap for: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Engelwood Daily
06/29/16 02:29 PMIs ANI Pharmaceuticals Inc a Buy? The Stock Rises Again - Press Telegraph
06/29/16 10:43 AMANI Pharmaceuticals Inc. (ANIP) Jumps 8.47% on June 28 - Equities.com
06/28/16 07:52 PMA Reversal for ANI Pharmaceuticals Inc Is Not Near. The Stock Rises Again - Press Telegraph
06/28/16 07:52 PMANI Pharma (ANIP) Announces Commercial Launch of HPC USP 250mg/mL in 5mL Vials - StreetInsider.com
06/28/16 07:46 AMGW Pharmaceuticals Stock Up on Positive Epidiolex Data

Social

About ANI Pharmaceuticals

ANI Pharmaceuticals logoANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company's focused areas of product development include anti-cancer (oncolytics), hormones and steroids, and complex formulations. Its generic products include Esterified Estrogen with Methyltestosterone, Etodolac, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup, Nimodipine, Opium Tincture, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Lithobid, Reglan and Vancocin. It has over two pharmaceutical manufacturing facilities located in Baudette, Minnesota that are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products. Its two facilities have a combined manufacturing, packaging and laboratory capacity totaling approximately 173,000 square feet.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ANIP
  • CUSIP:
Key Metrics:
  • Previous Close: $60.19
  • 50 Day Moving Average: $55.73
  • 200 Day Moving Average: $43.46
  • P/E Ratio: 56.19
  • P/E Growth: 1.07
  • Market Cap: $687.17M
  • Beta: 2.73
  • Current Year EPS Consensus Estimate: $3.38 EPS
  • Next Year EPS Consensus Estimate: $4.04 EPS
Additional Links:
ANI Pharmaceuticals (NASDAQ:ANIP) Chart for Thursday, July, 28, 2016